[Translation] Study on serum and lung drug concentrations, pharmacokinetics/pharmacodynamics and efficacy evaluation of long-term administration of tobramycin inhalation solution in the treatment of bronchiectasis patients with Pseudomonas aeruginosa infection

1) 评价妥布霉素吸入溶液在支气管扩张症（支扩症）伴铜绿假单胞菌（PA）感染患者中多次用药后在肺上皮衬液（ELF）和血清中的药物浓度及ELF到血液的渗透性； 2) 评价妥布霉素吸入溶液长疗程（12周）给药方案，治疗支扩症伴PA感染患者的细菌学指标变化； 3) 研究妥布霉素吸入溶液在支扩症伴PA感染患者中多次用药后的药代动力学（PK）/药效学（PD）与疗效相关性。

[Translation]

1) To evaluate the drug concentration of tobramycin inhalation solution in pulmonary epithelial lining fluid (ELF) and serum and the permeability of ELF to blood after multiple administration in patients with bronchiectasis (bronchiectasis) and Pseudomonas aeruginosa (PA) infection; 2) To evaluate the long-term (12-week) dosing regimen of tobramycin inhalation solution to treat the changes in bacteriological indicators in patients with bronchiectasis and PA infection; 3) To study the pharmacokinetics (PK)/pharmacodynamics (PD) and efficacy correlation of tobramycin inhalation solution in patients with bronchiectasis and PA infection after multiple administration.

Start Date10 Oct 2025

Sponsor / Collaborator

Healthy Yuan Haibin Pharmaceutical Co., Ltd.

[+1]

CTR20250988

/ RecruitingNot Applicable

雾化吸入妥布霉素治疗支气管扩张症急性加重患者伴铜绿假单胞菌感染的微生物学疗效研究：单中心，随机临床试验

[Translation] Microbiological efficacy of nebulized tobramycin in the treatment of Pseudomonas aeruginosa infection in patients with acute exacerbation of bronchiectasis: a single-center, randomized clinical trial

初步探索支扩症急性加重伴PA感染患者在全身抗感染基础上联合雾化吸入妥布霉素治疗，痰液PA 较治疗前的改变情况

[Translation]

Preliminary exploration of the changes in sputum PA in patients with acute exacerbation of bronchiectasis and PA infection treated with tobramycin nebulized inhalation on the basis of systemic anti-infection.

Start Date15 Aug 2025

Sponsor / Collaborator

Healthy Yuan Haibin Pharmaceutical Co., Ltd.

[+1]

ChiCTR2500105355

/ Not yet recruitingPhase 4IIT

Study on Serum and Pulmonary Drug Concentrations, Pharmacokinetics/Pharmacodynamics, and Efficacy Evaluation of Long-Term Tobramycin Inhalation Solution Regimen in Bronchiectasis Patients with Pseudomonas aeruginosa Infection

Start Date13 Jun 2025

Sponsor / Collaborator

The First Affiliated Hospital of Guangzhou Medical University

[+1]

100 Clinical Results associated with Tobramycin

100 Translational Medicine associated with Tobramycin

100 Patents (Medical) associated with Tobramycin

14,434

Literatures (Medical) associated with Tobramycin

01 Jan 2026·RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY

Analysis of the structure and surfactant activity of formulations with exogenous pulmonary surfactant as an antibiotic carrier

Article

Author: Martínez Sarrasague, María ; Facorro, Graciela ; Degrossi, José ; Cimato, Alejandra

Chronic respiratory diseases (CRD) account for approximately 15 % of global deaths annually, with respiratory infections being a significant cause of morbidity, especially in CRD patients. Inhaled antibiotics (ATBs) like Tobramycin and Gentamicin have shown promise in reducing microbial load and improving lung function. However, the conventional delivery methods-typically nebulization of formulations initially designed for systemic use-may result in undesirable side effects. This study explores the potential of utilizing exogenous pulmonary surfactant (EPS) as a carrier for pulmonary drug delivery, aiming to enhance antibiotic efficacy while minimizing systemic toxicity. We developed formulations combining EPS with commonly used ATBs (Amphotericin B, Levofloxacin, Gentamicin, and Itraconazole) and analyzed the macrostructure, bilayer organization, and surfactant activity of EPS. Using, UV and electron spin resonance (ESR) spectroscopies and pulsating bubble surfactometer, we evaluated the structural changes, bilayer fluidity and the surface properties. The results indicate that EPS can effectively integrate hydrophobic antibiotics, retain surfactant properties, while preserve its surface-active capabilities. Notably, Gentamicin significantly increased the proportion of the heavy surfactant fraction and modified the fluidity and lateral structure of the surfactant. The presence of Levofloxacin in EPS membranes slightly increased the bilayer rigidity without compromising surfactant functionality. These findings highlight the potential of EPS as a versatile carrier for targeted pulmonary antibiotic delivery, presenting a framework for the development of more effective treatments for pulmonary infections. Further exploration of the interaction between antibiotics and surfactant components is warranted to optimize formulation strategies in clinical applications.

31 Dec 2025·Virulence

Physiological role of bicarbonate in microbes: A double-edged sword?

Review

Author: Aspatwar, Ashok ; Parkkinen, Jenny ; Parkkila, Seppo

HCO₃^- is involved in pH homoeostasis and plays a multifaceted role in human health. HCO₃^- has been recognized for its antimicrobial properties and is pivotal in bacterial antibiotic susceptibility. Notably, the interconversion between CO₂ and HCO₃^-, facilitated by the enzyme carbonic anhydrase (CA), is crucial in tissues infected by pathogens. Studies have highlighted the antimicrobial potency of CA inhibitors, emphasizing the importance of this enzyme in this area. The potential of HCO₃^- as an antibiotic adjuvant is evident; its ability to increase virulence in pathogens such as Enterococcus faecalis and Mycobacterium tuberculosis requires meticulous scrutiny. HCO₃^- modulates bacterial behaviours in diverse manners: it promotes Escherichia coli O157:H7 colonization in the human gut by altering specific gene expression and, with Pseudomonas aeruginosa, amplifies the effect of tobramycin on planktonic cells while promoting biofilm formation. These multifaceted effects necessitate profound mechanistic exploration before HCO₃^- can be considered a promising clinical adjuvant.

01 Dec 2025·MOLECULAR BIOLOGY REPORTS

Targeted inhibition of PqsR in Pseudomonas aeruginosa PAO1 quorum-sensing network by chalcones as promising antibacterial compounds

Article

Author: Soheili, Vahid ; Tajani, Amineh Sadat ; Bazzaz, Bibi Sedigheh Fazly ; Rezaei, Tahoura ; Hashemi, Maryam ; Ghodsi, Razieh ; Arami, Negin

BACKGROUND:

Pseudomonas aeruginosa's inherent and adapted resistance makes this pathogen a serious problem for antimicrobial treatments. Furthermore, its biofilm formation ability is the most critical armor against antimicrobial therapy, and the virulence factors, on the other hand, contribute to fatal infection and other recalcitrant phenotypic characteristics. These capabilities are harmonized through cell-cell communication called Quorum Sensing (QS), which results in gene expression regulation via three major interconnected circuits: las, rhl, and pqs system. Pqs circuit specificity in P. aeruginosa made this system an attractive target for antipseudomonal therapy. The current study focuses on novel chalcone derivatives that attenuate P. aeruginosa's pathogenicity by inhibiting the QS system. Chalcones are included in the flavonoid class of phenolic compounds. This family forms one of the greatest groups of bioactive natural products.

METHOD:

The chalcone derivatives's potential activity against the QS system was evaluated through biofilm inhibition, decreased virulence factors production, and gene expression.

RESULTS:

Among all the tested compounds, 5H and NMe₂ chalcone derivatives reduced biofilm formation by 60.9% and 78.9%, respectively, and virulence factors production, including pyocyanin (decreased by 5H 30.9% and NMe2 30.7%) and pyoverdine (decreased by 5H 47.1% and NMe2 56.9%) and the QS gene expression (LasR, RhlR, and PqsR) more effectively than other derivatives.

CONCLUSION:

These chalcone compounds can be used as a supplement besides antimicrobial chemotherapy to attenuate pseudomonas pathogenicity.

News (Medical) associated with Tobramycin

10 Nov 2025

·investors.hcwbiologics.com

HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer

HCW11-040 is a first-in-class pembrolizumab-based, tetra-valent immune checkpoint inhibitor designated as Company’s franchise immunotherapeutic for internal clinical development MIRAMAR, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced today the latest updated data for its tetra-valent, second-generation pembrolizumab-based Immune Checkpoint Inhibitor (“ICI”) Program constructed using the Company’s novel TRBC platform, presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC2025”) which took place from November 5 to 9, 2025 in National Harbor, MD. The Company’s lead product candidate in its ICI program, HCW11-040, is a novel multi-functional fusion protein molecule, constructed with a unique combination IL-15 and IL-7 domains and a Transforming Growth Factor β (“TGF-β”) trap. It demonstrates PD-1/PD-L1 blocking activity equivalent to pembrolizumab (generic form of Keytruda®) in preclinical studies. Results of these preclinical studies also highlight the advantages of HCW11-040 over the first generation immune checkpoint inhibitors: To improve efficacy, HCW11-040 is equipped with other moieties in addition to pembrolizumab which neutralizes the immunosuppressive cytokine, TGF-β, and activates effector immune cell responses. The mouse homologue of HCW11-040 expands progenitor exhausted T (TPEX) cells significantly better than mouse ICI or pembrolizumab alone. TPEX cells are a key subset of T cells that respond to ICIs. TPEX cells have self-renewal capabilities and are considered a primary driver for the success of ICI therapies, making them an attractive target for improving treatment outcomes. HCW11-040 expands and activates human peripheral blood lymphocytes (PBMCs) and memory T cells significantly better than pembrolizumab alone. HCW11-040 exhibits significantly better anti-tumor activity of human PBMC against human pancreatic cancer and leukemia cells in organoid models than pembrolizumab alone. HCW11-040 leaves no evidence of inducing excessive inflammatory responses from the immune cells after subcutaneous administration. Subcutaneous administration expected to improve safety and quality-of-life for patients. Streamlined GMP manufacturing process is similar to the process used for therapeutic monoclonal antibodies. Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer, stated, “The preclinical data we shared at SITC2025 showed the details related to our discovery and selection of HCW11-040 as our franchise-building molecule for cancer and other age-related diseases. Our data shows that we verified the ability of HCW11-040 to expand and activate TPEX cells and promote anti-tumor activity of human peripheral blood mononuclear cells against human cancer cells without triggering cytokine storm side effects. Based on these encouraging results, we will vigorously advance additional IND-enabling studies for HCW11-040, including the creation of a high-expression manufacturing cell bank, manufacturing process development, and preclinical Good Laboratory Practice toxicology studies.” KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. and the company is not affiliated with HCWB. About HCW Biologics: HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients’ quality of life and potentially extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening. The Company’s lead product candidate, HCW9302, was developed using the Company’s legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics are being developed for treatment of a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform. Further preclinical evaluation studies are currently being conducted for these molecules the Company has selected based on promising preclinical data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. Forward Looking Statements: Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include, the actual success and potency of pembrolizumab-based TRBC fusion molecules; the ability of pembrolizumab-based TRBC fusion molecules to be equivalent to pembrolizumab alone including the ability of HCW11-040 to expand TPEX cells more effectively and expand and activate PBMCs more effectively; whether pembrolizumab-based TRBC fusion molecules will exhibit potent anti-pancreatic cancer and anti-leukemia activities and continue to outperform pembrolizumab both in vitro and in humanized mouse models; or whether pembrolizumab-based TRBC fusion molecules are effective in treatment of solid tumors and pancreatic cancers. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 28, 2025, the latest Form 10-Q filed with the SEC on August 18, 2025 and in other filings filed from time to time with the SEC. Company Contact: Dr. Peter Rhode Chief Scientific Officer and Vice President of Clinical Operations HCW Biologics Inc. PeterRhode@HCWBiologics.com

ImmunotherapyAACR

30 Oct 2025

·www.globenewswire.com

Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution

- Generic Tobramycin Inhalation Solution marks the first cystic fibrosis (CF) product in the Company’s portfolio-Antibiotic is primarily used for chronic Pseudomonas aeruginosa infections in patients with CF COLUMBIA, S.C., Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Ritedose Corporation (Ritedose) announced that the U.S. Food and Drug Administration (FDA) approved its manufacturing and distribution of Tobramycin Inhalation Solution to treat patients six years and older with infections of Pseudomonas aeruginosa, a common bacterial infection among cystic fibrosis patients. Tobramycin will be marketed by Ritedose Pharmaceuticals, the generics division of Ritedose (the largest sterile contract development manufacturing organization (CDMO) in the U.S., specializing in aseptic unit-dose medication production using Blow-Fill-Seal (BFS) technology). Ritedose licensed the drug’s Abbreviated New Drug Application (ANDA) from Hikma Pharmaceuticals. “With the addition of Tobramycin, Ritedose now provides the largest nebulized drug portfolio in the country,” said CEO of Ritedose Jody Chastain. “Our recent investments in expanded facilities, cold chain processes and an additional packaging line have given us unparalleled capabilities in sterile manufacturing.” Tobramycin is an aminoglycoside antibiotic indicated for the treatment of serious bacterial infections, including Pseudomonas aeruginosa (P.aeruginosa), in adults and pediatric patients six years of age and older. The Ritedose formulation is preservative-free and packaged as 300 mg doses in 5 ml ampules, to be administered through a nebulizer device. The medication is now available for purchase. “Now with Tobramycin in our portfolio, we can provide affordable, safe and reliable medications to patients with serious bacterial infections, expanding access to this critical therapy,” continued Chastain. “We’re also proud to strengthen supply chain resilience with the addition of a broad-spectrum antibiotic that is produced here in the United States.” Tobramycin Inhalation Solution is the third generic drug announced by Ritedose this year. In April, Ritedose Pharmaceuticals received approval to manufacture generic Formoterol Fumarate Inhalation Solution for the maintenance treatment of chronic obstructive pulmonary disease (COPD). In March, Ritedose received approval for Albuterol Sulfate Inhalation Solution, 0.5% (2.5 mg/0.5 mL)*, for patients over 12 years of age suffering from acute attacks of bronchospasms or reversible obstructive airway disease. The addition rounded out Ritedose’s complete portfolio of albuterol treatments and addressed a nationwide shortage of the essential drug. *Potency expressed as albuterol, equivalent to 3 mg of albuterol sulfate. About The Ritedose Corporation Ritedose is the largest sterile contract development manufacturing organization (CDMO) in the US specializing in sterile Blow Fill Seal (BFS) technology that ensures sterile, consistent, and safe unit dose delivery. The company’s process guides the development of molecules from clinical trials to commercialization of branded and generic inhalation and ophthalmic medications. With a focus on quality, innovation, and customer satisfaction, Ritedose partners with leading pharmaceutical companies to deliver safe, effective, and reliable medications that improve patient outcomes. Ritedose: Passion and Precision with a Purpose. For more information visit Ritedose.com Media Contact: Alex Keown630-346-5141akeown@inspire-agency.comOn Behalf of Ritedose A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/39b2ff09-2585-4764-93e1-4dd9766dc9fc

Drug Approval

23 Oct 2025

·www.einpresswire.com

FDA Rationale for Recognition Decision: Gentamicin, Tobramycin, and Amikacin for Enterobacterales and P. aeruginosa

FDA has completed its review of the rationale document titled, “Aminoglycoside Breakpoints for Enterobacterales and Pseudomonas aeruginosa ” submitted by the Clinical and Laboratory Standards Institute (CLSI) to the public docket FDA-2017-N-5925-0037 in January 2025. 1 Gentamicin, tobramycin, and amikacin are aminoglycoside antibacterial drugs approved for the treatment of serious infections including those caused by P. aeruginosa and several Enterobacterales species. In March 2023, the Clinical and Laboratory Standards Institute (CLSI) published revised breakpoints for gentamicin, tobramycin, and amikacin against Enterobacterales and P. aeruginosa in their M100-Ed 33 supplement. For Enterobacterales CLSI lowered the gentamicin, tobramycin, and amikacin breakpoints (Table 1). For P. aeruginosa , CLSI removed the gentamicin breakpoints, lowered the tobramycin breakpoints, and left the amikacin breakpoints numerically unchanged but limited their applicability to urinary isolates only (Table 2). Table 1. Historical a and Current b CLSI Gentamicin, Tobramycin, and Amikacin Breakpoints against Enterobacterales Minimum Inhibitory Concentrations (mcg/mL) Disk Diffusion (zone diameter in mm) S I R S I R Gentamicin Historical ≤ 4 8^ ≥ 16 ≥ 15 13 - 14^ ≤ 12 Current ≤ 2 4^ ≥ 8 ≥ 18 15 - 17^ ≤ 14 Tobramycin Historical ≤ 4 8^ ≥ 16 ≥ 15 13 - 14^ ≤ 12 Current ≤ 2 4^ ≥ 8 ≥ 17 13 - 16^ ≤ 12 Amikacin Historical ≤ 16 32^ ≥ 64 ≥ 17 15 - 16^ ≤ 14 Current ≤ 4 8^ ≥ 16 ≥ 20 17 - 19^ ≤ 16 S = Susceptible; I = Intermediate; R = Resistant; MIC = minimum inhibitory concentration ^, designation for agents that have the potential to concentrate in the urine a These breakpoints have been recognized by FDA. b First published in CLSI M100-Ed33, March 2023. Table 2. Historical a and Current b CLSI Gentamicin, Tobramycin, and Amikacin Breakpoints against Pseudomonas aeruginosa Minimum Inhibitory Concentrations (mcg/mL) Disk Diffusion (zone diameter in mm) S I R S I R Gentamicin Historical ≤ 4 8^ ≥ 16 ≥ 15 13 - 14^ ≤ 12 Current - - - - - - Tobramycin Historical ≤ 4 8^ ≥ 16 ≥ 15 13 - 14^ ≤ 12 Current ≤ 1 2^ ≥ 4 ≥ 19 13 - 18^ ≤ 12 Amikacin Historical ≤ 16 32^ ≥ 64 ≥ 17 15 - 16^ ≤ 14 Current (U) c ≤ 16 32^ ≥ 64 ≥ 17 15 - 16^ ≤ 14 S = Susceptible; I = Intermediate; R = Resistant; MIC = minimum inhibitory concentration ^, designation for agents that have the potential to concentrate in the urine a These breakpoints have been recognized by FDA. b First published in CLSI M100-Ed33, March 2023. c (U) for reporting on urinary isolates only The dosing regimens that were used to establish the CLSI breakpoints include 7 mg/kg intravenously (IV) every 24 hours for gentamicin and tobramycin, and 15 mg/kg IV every 24 hours for amikacin. To minimize dissection of the wild-type bacterial population and preserve reproducibility of susceptibility testing, CLSI used the net bacterial stasis endpoint in the probability of target attainment (PTA) analyses because 1-log colony-forming unit (CFU) reduction was not attainable for MICs representing the high end of the wild-type population, i.e., the epidemiological cutoff MIC. Moreover, for P. aeruginosa and gentamicin and amikacin, even the net stasis endpoint was not attainable for a large segment of the wild population. Consequently, CLSI eliminated the gentamicin breakpoints against P. aeruginosa . Amikacin breakpoints for P. aeruginosa were retained but limited to urinary isolates only on the basis that amikacin concentrates in the urine and that clinical efficacy data demonstrate that favorable outcomes are most reliable for infections originating in the urinary tract. FDA acknowledges the limitations of the data but agrees that the revised breakpoints would be more predictive of clinical outcomes as compared to the currently recognized FDA breakpoints, and therefore, recognizes the CLSI gentamicin, tobramycin, and amikacin breakpoints for Enterobacterales and P. aeruginosa as displayed above. 1 Comment from Clinical and Laboratory Standards Institute (CLSI) Content current as of: 10/23/2025 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Qualified Infectious Disease ProductDrug ApprovalClinical Result

100 Deals associated with Tobramycin

External Link

KEGG	Wiki	ATC	Drug Bank
D00063	Tobramycin	S01AA12 J01GB01	DB00684

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bronchiectasis	China	Joincare Pharmaceutical Group Industry Co., Ltd.	11 Oct 2022
Cystic Fibrosis	Japan	Viatris Healthcare GK	28 Sep 2012
Cystic Fibrosis	Japan	Viatris Pharmaceutical GK	28 Sep 2012
Infectious Lung Disorder	European Union	Viatris Healthcare (Pty) Ltd.	20 Jul 2011
Infectious Lung Disorder	Iceland	Viatris Healthcare (Pty) Ltd.	20 Jul 2011
Infectious Lung Disorder	Liechtenstein	Viatris Healthcare (Pty) Ltd.	20 Jul 2011
Infectious Lung Disorder	Norway	Viatris Healthcare (Pty) Ltd.	20 Jul 2011
Pseudomonas Infections	United States	Viatris Specialty LLC	22 Dec 1997
Acute Bronchitis	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Cystitis	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Hemorrhagic Septicemia	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Peritonitis	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Pneumonia	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Pyelonephritis	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Pyoderma	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Secondary infection	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Blepharitis	Japan	Nitto Medic Co., Ltd.	07 Dec 1981
Conjunctivitis	Japan	Nitto Medic Co., Ltd.	07 Dec 1981
Corneal Ulcer	Japan	Nitto Medic Co., Ltd.	07 Dec 1981
Dacryocystitis	Japan	Nitto Medic Co., Ltd.	07 Dec 1981

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pseudomonas aeruginosa infection	Phase 3	Estonia	Novartis Pharmaceuticals Canada, Inc.	12 Aug 2009
Pseudomonas aeruginosa infection	Phase 3	Russia	Novartis Pharmaceuticals Canada, Inc.	12 Aug 2009
Cataract	Phase 3	United States	Bausch & Lomb, Inc.	01 Feb 2009
Eye Infections	Phase 3	United States	Bausch & Lomb, Inc.	01 Jul 2005
Postoperative Complications	Phase 3	United States	Bausch & Lomb, Inc.	01 Jul 2005
Non-cystic fibrosis bronchiectasis	Phase 2	Belgium	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	France	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	Germany	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	Italy	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	Spain	Novartis Pharmaceuticals Corp.	08 Feb 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03705962 (CTgov)	Phase 3	Fractures, Open \| Infectious Diseases	11	Tobramycin (Antibiotic)	mhphapjpdp = satdydvqvh cialkqibfm (rrqwkhonha, blycaqpunt - nrphchayof) View more	-	15 Jun 2023
				Placebo: normal saline (Normal Saline)	mhphapjpdp = pvzffzcvvf cialkqibfm (rrqwkhonha, ruoyoccxlp - byxthzmrsq) View more
NCT02478710 (AAINTVAP, CTgov)	Phase 4	Pneumonia, Ventilator-Associated	16	Aerosolized Placebo (Aerosolized Placebo)	dbpdedgjwt(wlqemntdmn) = gennrijvus pxpyvrnbvq (gfkazpokbl, mltlzwxptj - mlmmxlcgpe) View more	-	22 May 2023
				Tobramycin+Vancomycin (Aerosolized Tobramycin or Vancomycin)	dbpdedgjwt(wlqemntdmn) = gennqbmyon pxpyvrnbvq (gfkazpokbl, vwlniexszy - vqonqhvlyc) View more
NCT02657473 (The BATTLE study, Pubmed \| Respir Res)	Phase 2/3	Non-cystic fibrosis bronchiectasis Maintenance	58	Tobramycin inhalation solution (TIS)	mdwwvlkdkz(yfdjujeapt): RR = 0.74 (95% CI, 0.49 - 1.14), P-Value = 0.15	-	03 Dec 2022
				Placebo
NCT02918409 (CTgov)	Phase 4	Cystic Fibrosis	51	Colistin (Standard Colistin Arm)	smuleqvcyt(cosfrwkzri) = xiokeicrns qwtirgfcqu (quogcoddjk, 9.5) View more	-	06 Oct 2022
				Colistin (Modified Colistin Arm)	smuleqvcyt(cosfrwkzri) = rfjmmlfhes qwtirgfcqu (quogcoddjk, 3.0) View more
NCT03673956 (CTgov)	Phase 1/2	Chronic sinusitis	19	Tobramycin (Tobramycin Topical Antibiotic Nasal Saline Rinse)	pvvjgydjsn = pqajlleuct wbwglidbol (ukptkncvnw, upbtpmgazv - vtldlhazvw) View more	-	20 Apr 2022
				levofloxacin (Levofloxacin Topical Antibiotic Nasal Saline Rinse)	pvvjgydjsn = jlgmulvsqn wbwglidbol (ukptkncvnw, gszfrknurn - qggefhxzuk) View more
NCT04297631 (CTgov)	Phase 4	-	20	Tobramycin+Vancomycin (Intraarticular Concentrations of Tobramycin and Vancomycin)	psthrsaukk(mfxsciydro) = jqhqdpohuo lcwgryxdwq (tqkjenuvfs, zmgfdnhqfo - ezesiahzsh) View more	-	05 Oct 2021
				Tobramycin+Vancomycin (Vancomycin and Tobramycin Serum Concentration)	snszwqzzek(nvorzunfvw) = ehmhmqteci vwwcfafhsp (quqwcvrtqg, nkeeavkahu - sufkkxwwts) View more
NCT01069705 (CTgov)	Phase 3	Pseudomonas Infections \| Pseudomonas aeruginosa infection \| Cystic Fibrosis ... View more	49	Tobramycin inhalation powder	wtemxzlxxu = dmhgsvysgz whgaugoqfj (luvuyflfdz, xhplhazreg - zikeoeegst) View more	-	02 Jun 2021
NCT00982930 (CTgov)	Phase 3	Pseudomonas aeruginosa infection \| Cystic Fibrosis	55	Tobramycin	khkkugwhtq = zqcnfplydj pkmqhvumqw (xjkpxvzhjo, oquczauskl - pjeezmypex) View more	-	02 Jun 2021
NCT02712983 (iBEST study, Pubmed \| Eur Respir J)	Phase 2	Non-cystic fibrosis bronchiectasis Pseudomonas aeruginosa	107	Tobramycin inhalation powder (TIP) 84mg once daily	jfyhleelrm(xhwlodwttj) = 37.4% wihcodqntw (yymafzkuku ) View more	-	01 Jan 2021
				Tobramycin inhalation powder (TIP) 140mg once daily
NCT02212587 (CTgov)	Phase 1	Cystic Fibrosis \| Burkholderia Infections	10	TOBI	etfctxtyvh(wfowdldwee) = ufiopcjxyd anehkwofce (atoxmghsna, egdriulxwe - zrmbrpjsbe) View more	-	04 Nov 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis